Abstract
Atherosclerosis is an inflammatory disease. Both innate and adaptive immunity are involved in lesion formation and development. A number of antigen candidates, such as oxidized low-density lipoprotein and heat shock protein, have been associated with the inflammation and immune reaction that is part of the atherosclerotic process. Because experimental models of some other inflammatory/autoimmune diseases can be improved by vaccination, it is of interest to investigate if vaccination can also be applied to prevent or retard atherosclerosis. Indeed, the modification of immune responses in animal models can greatly affect the development and progression of atherosclerosis. This review provides an overview of our current understanding of effects and proposed mechanisms of immunization on preventing atherosclerosis.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Binder CJ, Chang MK, Shaw PX, et al.: Innate and acquired immunity in atherogenesis. Nat Med 2002, 8:1218–1226.
Hansson GK, Libby P, Schonbeck U, et al.: Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 2002, 91:281–291.
Aliprantis AO, Yang RB, Mark MR, et al.: Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2. Science 1999, 285:736–739.
Griffith RL, Virella GT, Stevenson HC, et al.: Low density lipoprotein metabolism by human macrophages activated with low density lipoprotein immune complexes. A possible mechanism of foam cell formation. J Exp Med 1988, 168:1041–1059.
Xu XH, Shah PK, Faure E, et al.: Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 2001, 104:3103–3108.
Brown MS, Goldstein JL: A receptor-mediated pathway for cholesterol homeostasis. Science 1986, 232:34–47.
Suzuki H, Kurihara Y, Takeya M, et al.: A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature 1997, 386:292–296.
Febbraio M, Podrez EA, Smith JD, et al.: Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest 2000, 105:1049–1056.
Zhou X: CD4+ T cells in atherosclerosis. Biomed Pharmacother 2003, 57:287–291.
Jonasson L, Holm J, Skalli O, et al.: Expression of class II transplantation antigen on vascular smooth muscle cells in human atherosclerosis. J Clin Invest 1985, 76:125–131.
Hansson GK, Holm J, Jonasson L: Detection of activated T lymphocytes in the human atherosclerotic plaque. Am J Pathol 1989, 135:169–175.
Gupta S, Pablo AM, Jiang XC, et al.: IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J Clin Invest 1997, 99:2752–2761.
Zhou X, Nicoletti A, Elhage R, et al.: Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation 2000, 102:2919–2922.
Song L, Leung C, Schindler C: Lymphocytes are important in early atherosclerosis. J Clin Invest 2001, 108:251–259.
Buono C, Come CE, Stavrakis G, et al.: Influence of interferon-gamma on the extent and phenotype of diet-induced atherosclerosis in the LDLR-deficient mouse. Arterioscler Thromb Vasc Biol 2003, 23:454–460.
Whitman SC, Ravisankar P, Elam H, et al.: Exogenous interferon-gamma enhances atherosclerosis in apolipoprotein E-/- mice. Am J Pathol 2000, 157:1819–1824.
Sohma Y, Sasano H, Shiga R, et al.: Accumulation of plasma cells in atherosclerotic lesions of Watanabe heritable hyperlipidemic rabbits. Proc Natl Acad Sci U S A 1995, 92:4937–4941.
Salonen JT, Yla-Herttuala S, Yamamoto R, et al.: Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 1992, 339:883–887.
Ylä-Herttuala S, Palinski W, Butler SW, et al.: Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb 1994, 14:32–40.
Seifert PS, Hansson GK: Decay-accelerating factor is expressed on vascular smooth muscle cells in human atherosclerotic lesions. J Clin Invest 1989, 84:597–604.
Seifert PS, Hugo F, Tranum-Jensen J, et al.: Isolation and characterization of a complement-activating lipid extracted from human atherosclerotic lesions. J Exp Med 1990, 172:547–557.
Nicoletti A, Kaveri S, Caligiuri G, et al.: Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice. J Clin Invest 1998, 102:910–918.
Caligiuri G, Nicoletti A, Poirier B, et al.: Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. J Clin Invest 2002, 109:745–753.
Backlund J, Treschow A, Bockermann R, et al.: Glycosylation of type II collagen is of major importance for T cell tolerance and pathology in collagen-induced arthritis. Eur J Immunol 2002, 32:3776–3784.
Weiner HL, Selkoe DJ: Inflammation and therapeutic vaccination in CNS diseases. Nature 2002, 420:879–884.
Mallat Z, Besnard S, Duriez M, et al.: Protective role of interleukin-10 in atherosclerosis. Circ Res 1999, 85:e17-e24.
Smith JD, Trogan E, Ginsberg M, et al.: Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc Natl Acad Sci U S A 1995, 92:8264–8268.
Elhage R, Maret A, Pieraggi MT, et al.: Differential effects of interleukin-1 receptor antagonist and tumor necrosis factor binding protein on fatty-streak formation in apolipoprotein E-deficient mice. Circulation 1998, 97:242–244.
Mach F, Schonbeck U, Sukhova GK, et al.: Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 1998, 394:200–203.
Palinski W, Rosenfeld ME, Yla HS, et al.: Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci U S A 1989, 86:1372–1376.
Nicoletti A, Caligiuri G, Tornberg I, et al.: The macrophage scavenger receptor type A directs modified proteins to antigen presentation. Eur J Immunol 1999, 29:512–521.
Stemme S, Faber B, Holm J, et al.: T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci U S A 1995, 92:3893–3897.
Palinski W, Horkko S, Miller E, et al.: Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. J Clin Invest 1996, 98:800–814.
Schumacher M, Eber B, Tatzber F, et al.: LDL oxidation and coronary atherosclerosis [letter; comment]. Lancet 1992, 340:123.
Seifert PS, Kazatchkine MD: Generation of complement anaphylatoxins and C5b-9 by crystalline cholesterol oxidation derivatives depends on hydroxyl group number and position. Mol Immunol 1987, 24:1303–1308.
Latron Y, Chautan M, Anfosso F, et al.: Stimulating effect of oxidized low density lipoproteins on plasminogen activator inhibitor-1 synthesis by endothelial cells. Arterioscler Thromb 1991, 11:1821–1829.
Kume N, Cybulsky MI, Gimbrone MJ: Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J Clin Invest 1992, 90:1138–1144.
Muller K, Hardwick SJ, Marchant CE, et al.: Cytotoxic and chemotactic potencies of several aldehydic components of oxidised low density lipoprotein for human monocyte-macrophages. FEBS Lett 1996, 388:165–168.
Terkeltaub R, Banka CL, Solan J, et al.: Oxidized LDL induces monocytic cell expression of interleukin-8, a chemokine with T-lymphocyte chemotactic activity. Arterioscler Thromb Vasc Biol 1994, 14:47–53.
Jovinge S, Ares MP, Kallin B, et al.: Human monocytes/macrophages release TNF-alpha in response to Ox-LDL. Arterioscler Thromb Vasc Biol 1996, 16:1573–1579.
Uyemura K, Demer LL, Castle SC, et al.: Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J Clin Invest 1996, 97:2130–2138.
Wuttge DM, Eriksson P, Sirsjo A, et al.: Expression of interleukin-15 in mouse and human atherosclerotic lesions. Am J Pathol 2001, 159:417–423.
Ross R: Atherosclerosis—an inflammatory disease. N Engl J Med 1999, 340:115–126.
Palinski W, Miller E, Witztum JL: Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci U S A 1995, 92:821–825.
Zhou X, Caligiuri G, Hamsten A, et al.: LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis. Arterioscler Thromb Vasc Biol 2001, 21:108–114.
Nilsson J, Calara F, Regnström J, et al.: Immunization with homologous oxidized low density lipoprotein reduces neointimal formation after balloon injury in hypercholesterolemic rabbits. J Am Coll Cardiol 1997, 30:1886–1891.
Nordin-Fredrikson G, Soderberg I, Lindholm M, et al.: Inhibition of atherosclerosis in apoE-null mice by immunization with apoB-100 peptide sequences. Arterioscler Thromb Vasc Biol 2003, 23:879–884.
Sherer Y, Shoenfeld Y: Immunomodulation for treatment and prevention of atherosclerosis. Autoimmun Rev 2002, 1:21–27.
Wick G: Atherosclerosis—an autoimmune disease due to an immune reaction against heat-shock protein 60. Herz 2000, 25:87–90.
Frostegård J, Kjellman B, Gidlund M, et al.: Induction of heat shock protein in monocytic cells by oxidized low density lipoprotein. Atherosclerosis 1996, 121:93–103.
Mayr M, Metzler B, Kiechl S, et al.: Endothelial cytotoxicity mediated by serum antibodies to heat shock proteins of Escherichia coli and Chlamydia pneumoniae: immune reactions to heat shock proteins as a possible link between infection and atherosclerosis. Circulation 1999, 99:1560–1566.
Berberian PA, Myers W, Tytell M, et al.: Immunohistochemical localization of heat shock protein-70 in normal- appearing and atherosclerotic specimens of human arteries. Am J Pathol 1990, 136:71–80.
Xu Q, Kleindienst R, Waitz W, et al.: Increased expression of heat shock protein 65 coincides with a population of infiltrating T lymphocytes in atherosclerotic lesions of rabbits specifically responding to heat shock protein 65. J Clin Invest 1993, 91:2693–2702.
Xu Q, Kiechl S, Mayr M, et al.: Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis: clinical significance determined in a follow-up study [see comments]. Circulation 1999, 100:1169–1174.
George J, Shoenfeld Y, Afek A, et al.: Enhanced fatty streak formation in C57BL/6J mice by immunization with heat shock protein-65. Arterioscler Thromb Vasc Biol 1999, 19:505–510.
George J, Afek A, Gilburd B, et al.: Cellular and humoral immune responses to heat shock protein 65 are both involved in promoting fatty-streak formation in LDL-receptor deficient mice. J Am Coll Cardiol 2001, 38:900–905.
Kol A, Lichtman AH, Finberg RW, et al.: Cutting edge: heat shock protein (HSP) 60 activates the innate immune response: CD14 is an essential receptor for HSP60 activation of mononuclear cells. J Immunol 2000, 164:13–17.
Maron R, Sukhova G, Faria AM, et al.: Mucosal administration of heat shock protein-65 decreases atherosclerosis and inflammation in aortic arch of low-density lipoprotein receptor-deficient mice. Circulation 2002, 106:1708–1715.
Faria AM, Weiner HL: Oral tolerance: mechanisms and therapeutic applications. Adv Immunol 1999, 73:153–264.
Saikku P, Leinonen M, Mattila K, et al.: Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988, 2:983–986.
Kuo CC, Gown AM, Benditt EP, et al.: Detection of Chlamydia pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stain. Arterioscler Thromb 1993, 13:1501–1504.
Vink A, Poppen M, Schoneveld AH, et al.: Distribution of Chlamydia pneumoniae in the human arterial system and its relation to the local amount of atherosclerosis within the individual. Circulation 2001, 103:1613–1617.
Thomas M, Wong Y, Thomas D, et al.: Relation between direct detection of Chlamydia pneumoniae DNA in human coronary arteries at postmortem examination and histological severity (Stary grading) of associated atherosclerotic plaque. Circulation 1999, 99:2733–2736.
Danesh J, Whincup P, Walker M, et al.: Chlamydia pneumoniae IgG titres and coronary heart disease: prospective study and meta-analysis. BMJ 2000, 321:208–213.
Fong IW, Chiu B, Viira E, et al.: De novo induction of atherosclerosis by Chlamydia pneumoniae in a rabbit model. Infect Immun 1999, 67:6048–6055.
Moazed TC, Campbell LA, Rosenfeld ME, et al.: Chlamydia pneumoniae infection accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. J Infect Dis 1999, 180:238–241.
Caligiuri G, Rottenberg M, Nicoletti A, et al.: Chlamydia pneumoniae infection does not induce or modify atherosclerosis in mice. Circulation 2001, 103:2834–2838.
Aalto-Setala K, Laitinen K, Erkkila L, et al.: Chlamydia pneumoniae does not increase atherosclerosis in the aortic root of apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2001, 21:578–584.
Gupta S, Leatham EW, Carrington D, et al.: Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997, 96:404–407.
Gurfinkel E, Bozovich G, Daroca A, et al.: Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. ROXIS Study Group. Lancet 1997, 350:404–407.
O’Connor CM, Dunne MW, Pfeffer MA, et al.: Azithromycin for the second prevention of coronary heart disease events. The WIZARD study: a randomized controlled trial. JAMA 2003, 290:1459–1466.
Hörkkö S, Bird DA, Miller E, et al.: Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J Clin Invest 1999, 103:117–128.
Shaw PX, Hörkkö S, Chang MK, et al.: Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Invest 2000, 105:1731–1740.
Binder CJ, Hörkkö S, Dewan A, et al.: Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med 2003, 9:736–743.
Epstein SE, Zhou YF, Zhu J: Infection and atherosclerosis: emerging mechanistic paradigms. Circulation 1999, 100:e20-e28.
McDonald K, Rector TS, Braulin EA, et al.: Association of coronary artery disease in cardiac transplant recipients with cytomegalovirus infection. Am J Cardiol 1989, 64:359–362.
Zhou YF, Leon MB, Waclawiw MA, et al.: Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N Engl J Med 1996, 335:624–630.
Alber DG, Powell KL, Vallance P, et al.: Herpesvirus infection accelerates atherosclerosis in the apolipoprotein E-deficient mouse. Circulation 2000, 102:779–785.
Hsich E, Zhou YF, Paigen B, et al.: Cytomegalovirus infection increases development of atherosclerosis in apolipoprotein-E knockout mice. Atherosclerosis 2001, 156:23–28.
Streblow DN, Soderberg-Naucler C, Vieira J, et al.: The human cytomegalovirus chemokine receptor US28 mediates vascular smooth muscle cell migration. Cell 1999, 99:511–520.
Group TE: Cold exposure and winter mortality from ischaemic heart disease, cerebrovascular disease, respiratory disease, and all causes in warm and cold regions of Europe. The Eurowinter Group. Lancet 1997, 349:1341–1346.
Meier CR, Jick SS, Derby LE, et al.: Acute respiratory-tract infections and risk of first-time acute myocardial infarction. Lancet 1998, 351:1467–1471.
Naghavi M, Barlas Z, Siadaty S, et al.: Association of influenza vaccination and reduced risk of recurrent myocardial infarction. Circulation 2000, 102:3039–3045.
Naghavi M, Wyde P, Litovsky S, et al.: Influenza infection exerts prominent inflammatory and thrombotic effects on the atherosclerotic plaques of apolipoprotein E-deficient mice. Circulation 2003, 107:762–768.
Wright SD, Burton C, Hernandez M, et al.: Infectious agents are not necessary for murine atherogenesis. J Exp Med 2000, 191:1437–1442.
George J, Harats D, Gilburd B, et al.: Immunolocalization of beta2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression. Circulation 1999, 99:2227–2230.
Sherer Y, Tenenbaum A, Praprotnik S, et al.: Coronary artery disease but not coronary calcification is associated with elevated levels of cardiolipin, beta-2-glycoprotein-I, and oxidized LDL antibodies. Cardiology 2001, 95:20–24.
George J, Afek A, Gilburd B, et al.: Induction of early atherosclerosis in LDL-receptor-deficient mice immunized with beta2-glycoprotein I. Circulation 1998, 98:1108–1115.
Hasunuma Y, Matsuura E, Makita Z, et al.: Involvement of beta 2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 1997, 107:569–573.
Barter P: CETP and atherosclerosis. Arterioscler Thromb Vasc Biol 2000, 20:2029–2031.
Hayek T, Masucci-Magoulas L, Jiang X, et al.: Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene. J Clin Invest 1995, 96:2071–2074.
Berard AM, Foger B, Remaley A, et al.: High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin-cholesteryl acyltransferase. Nat Med 1997, 3:744–749.
Foger B, Chase M, Amar MJ, et al.: Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice. J Biol Chem 1999, 274:36912–36920.
Plump AS, Masucci-Magoulas L, Bruce C, et al.: Increased atherosclerosis in ApoE and LDL receptor gene knockout mice as a result of human cholesteryl ester transfer protein transgene expression. Arterioscler Thromb Vasc Biol 1999, 19:1105–1110.
Rittershaus CW, Miller DP, Thomas LJ, et al.: Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol 2000, 20:2106–2112.
Lamb DJ, Avades TY, Ferns GA: Endogenous neutralizing antibodies against platelet-derived growth factor-aa inhibit atherogenesis in the cholesterol-fed rabbit. Arterioscler Thromb Vasc Biol 2001, 21:997–1003.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Zhou, X., Hansson, G.K. Vaccination and atherosclerosis. Curr Atheroscler Rep 6, 158–164 (2004). https://doi.org/10.1007/s11883-004-0105-7
Issue Date:
DOI: https://doi.org/10.1007/s11883-004-0105-7